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ABSTRACT: Aldehyde dehydrogenase enzymes irreversibly
oxidize aldehydes generated from metabolism of amino acids,
fatty acids, food, smoke, additives, and xenobiotic drugs.
Cyclophosphamide is one such xenobiotic used in cancer
therapies. Upon activation, cyclophosphamide forms an inter-
mediate, aldophosphamide, which can be detoxiﬁed to carbox-
yphosphamide by aldehyde dehydrogenases (ALDH), especially
ALDH1A1 and ALDH3A1. Consequently, selective inhibition of
ALDH3A1 could increase chemosensitivity toward cyclophospha-
mide in ALDH3A1 expressing tumors. Here, we report detailed
kinetics and structural characterization of a highly selective
submicromolar inhibitor of ALDH3A1, 1-[(4-ﬂuorophenyl)sulfonyl]-2-methyl-1H-benzimidazole (CB7, IC50 of 0.2 μM). CB7
does not inhibit ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, or ALDH2 activity. Structural, kinetics, and mutagenesis studies
show that CB7 binds to the aldehyde binding pocket of ALDH3A1. ALDH3A1-expressing lung adenocarcinoma and
glioblastoma cell lines are sensitized toward mafosfamide (MF) treatment in the presence analogues of CB7, whereas primary
lung ﬁbroblasts lacking ALDH3A1 expression, are not.
■ INTRODUCTION
Aldehydes are highly reactive compounds that can form adducts
with various cellular nucleophiles. Aldehyde dehydrogenases
(ALDH) catalyze the NAD(P)+-dependent oxidation of
aldehydes to their corresponding carboxylic acids. The high
cellular NAD+/NADH ratio makes the ALDH system an
eﬃcient process for eliminating unwanted aldehydes from cells.
Out of the 19 functional members of ALDH gene family1 only
a few have been characterized structurally, kinetically, and
through gene knockout studies. ALDH enzymes are involved in
variety of functions some of which include acetaldehyde
oxidation (catalyzed by ALDH2), production of retinoic acid
(ALDH1A isoforms), folate metabolism (ALDH1L1), metab-
olism of neurotransmitters (ALDH5A1), as well as proline and
branched-chain amino acid metabolism (ALDH4A1 and
ALDH6A1, respectively).1 Their function is also emphasized
by the fact that single nucleotide polymorphisms (SNPs)
leading to loss of enzyme function show serious physiological
complications. SNPs associated with the ALDH2*2 allele
(E487K or E504K) that is present in the East Asian population
are associated with impaired ethanol metabolism2 and reduced
eﬃcacy of nitroglycerin.3−5 Interestingly, inhibition of ALDH2
suppresses cocaine seeking behavior in rats6 whereas its
activation reduces myocardial infarct size induced by
ischemia−reperfusion.7−9 Functional polymorphisms in the
ALDH3A2 and ALDH4A1 genes lead to Sjögren−Larson
syndrome (SLS)10 and type II hyperprolinemia, respec-
tively.11,12 ALDH isozymes are also involved in cancer
progression and chemoresistance. ALDH1A1 is overexpressed
in many types of cancer and is considered to be a biomarker of
cancer stem cells.13,14 Enzyme kinetics and RNA knockdown
studies implicate ALDH isozymes, especially ALDH1A1 and
ALDH3A1, in the metabolic inactivation of aldophosphamide
to carboxyphosphamide (Figure 1), eﬀectively reducing the
eﬃcacy of cyclophosphamide in cancer treatment regi-
mens.15−17
ALDH3A1 is a cytosolic enzyme most highly expressed in
corneal tissues and keratinocytes, where it serves as a crystallin
and contributes to the elimination of various UV-induced lipid
peroxidation products, such as α,β-hydroxyalkenals and
malondialdehyde.18−20 It is not ubiquitously expressed in all
cell types, but its expression can be induced by various agents.21
Knockout studies have shown that Aldh3a1(−/−) deﬁcient
mice are viable.22 In addition to its expression in some normal
cells, ALDH3A1 is also heavily expressed in human tumors
such as hepatoma, lung adenocarcinoma, myeloma, breast
cancer, and stem cell populations.21,23−26 ALDH3A1 can
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catalyze the metabolic inactivation of oxazaphosphorines and
contribute to drug resistance in various tumor types.26 It is not
yet clear whether cancer cells induce ALDH3A1 expression
solely to metabolize xenobiotics or its expression is a
consequence of changes in the global gene expression pattern
in tumorigenic cells. A recent study showed that ALDH3A1 is a
downstream target of metadherin (MTDH), an important gene
involved in multidrug chemoresistance.27 In that study,
ﬁbroblastoid mammary carcinoma (LM2) cells expressing
inducible ALDH3A1 shRNA were more sensitive to chemo-
therapeutic agents such as paclitaxel, doxorubicin, and 4-
hydroxycyclophosphamide when ALDH3A1 was down-regu-
lated and chemoresistance to these same agents was increased
when ALDH3A1 was overexpressed.27 Diﬀerential expression
levels of ALDH3A1 account for the variable clinical responses
to cyclophosphamide treatment in certain cancers.28 In support
of this hypothesis, ALDH3A1 knockdown increases cellular
sensitivity to cyclophosphamide15 and transfection of
ALDH3A1 into normal human peripheral blood hematopoietic
progenitor cells results in increased resistance to cyclo-
phosphamide.29 Previous studies conducted in cultured
human colon carcinoma cell lines have shown that the colon
C cell line is 10-fold less sensitive to mafosfamide (analogue of
cyclophosphamide) than the RCA and HCT 116b colon cancer
cell lines, which express 200-fold lower levels of ALDH3A1.24
In contrast, all three cell lines (colon C, RCA, and HCT 116b)
were equally sensitive to phosphoramide mustard, the ﬁnal
activated product of cyclophosphamide metabolism that cannot
be detoxiﬁed by ALDH3A1 (Figure 1).24 The addition of
competitive substrates for ALDH3A1 to colon C cancer cells
reversed the resistance to mafosfamide,24 while the sensitivity of
HCT116b and RCA cells to mafosfamide was unaﬀected when
drug exposure was performed in the presence of the same
substrates.24 Another study demonstrated that electroporation
of ALDH3A1 into MCF-7 cells reduced their sensitivity to
mafosfamide 16-fold relative to control MCF-7 cells.30
Induction of ALDH3A1 in MCF-7 through treatment with
catechol yielded cells (MCF-7/CAT) that were more than 35-
fold more resistant to mafosfamide compared to control (MCF-
7) cells.21 Conversely, treatment of MCF-7/CAT cells with the
ALDH3A1 inhibitor chlorpropamide reduced their ED50 for
mafosfamide by 10-fold.25 However, the chlorpropamide class
of compounds is not selective for ALDH3A1 and also inhibits
ALDH2.31 More recently, a nonselective mechanism-based
inhibitor of ALDH isoenzymes enhanced sensitivity toward
mafosfamide in A549 cells.32 However, the nonselective nature
of these compounds makes it diﬃcult to determine the
individual contributions of each ALDH isozyme to the
sensitization.
Isozyme selective inhibitors for ALDH isozymes are few,
especially for ALDH3A1. Selective small molecule inhibitors of
ALDH3A1 could enhance the sensitivity of chemotherapeutic
agents such as cyclophosphamide analogues as well as tease out
the contributions to aldophosphamide metabolism in tumor
cells. Some antineoplastic agents induce apoptosis in cancer
cells by producing oxidative stress through generation of lipid
peroxidation products. Since ALDH3A1 can detoxify the
products of lipid peroxidation, it can facilitate drug resistance
in cancer cells that show high ALDH3A1 expression. Therefore,
selective small molecule inhibitors of ALDH3A1 can be helpful
in overcoming these eﬀects. Here, we report kinetic, structural,
and cellular characterization of a highly selective inhibitor for
ALDH3A1, designated CB7, previously identiﬁed in our high
throughput screen.33 When tested at concentrations up to 250
μM, CB7 showed no inhibition of ALDH1A1, ALDH1A2,
ALDH1A3, ALDH1B1, or ALDH2 activity. Enzyme kinetics
and crystallographic studies indicate that this compound is
competitive with respect to aldehyde binding and non-
competitive with respect to NADP+ binding. Treatment of
the ALDH3A1 expressing cell lines A549 (lung adenocarcino-
ma) and SF767 (glioblastoma) with mafosfamide in combina-
tion with 10 μM CB7, or analogues of CB7, enhanced the
antiproliferative eﬀects of mafosfamide, whereas treatment of
primary lung ﬁbroblasts (CCD-13Lu), which do not express
ALDH3A1, did not.
Figure 1. Metabolism of cyclophosphamide. Cyclophosphamide is oxidized by cytochrome P450 enzymes to 4-hydroxycyclophosphamide and its
isomer aldophosphamide. Aldophosphamide can undergo β-elimination to form acrolein and the phosphoramide mustard that alkylates DNA.
Alternatively, aldophosphamide can be oxidized to the inactive carboxyphosphamide by ALDH isoenzymes (ALDH1A1 and ALDH3A1).
Mafosfamide does not require P450 action for activation and undergoes spontaneous hydrolysis to form 4-hydroxycyclophosphamide.
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■ RESULTS
Kinetic Characterization of CB7. CB7 emerged from our
original high-throughput screen as a selective inhibitor of
ALDH3A133 (Figure 2A). CB7 has a molecular mass of 290 Da
and has no structural similarity to any known inhibitors of
aldehyde dehydrogenases. The compound has good potency
(IC50 of 0.2 ± 0.05 μM) for an initial hit compound against
ALDH3A1 (Figure 2B) and good selectivity with no eﬀect on
ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, or ALDH2
activity up to 250 μM. CB7 exhibits a competitive mode of
inhibition with respect to varied benzaldehyde, with a Ki of 82
± 6 nM, and a noncompetitive mode of inhibition with respect
to varied NADP+, with a Ki of 110 ± 3 nM (Figure 3A and
Figure 3B).
Structure−Activity Relationship of CB7 Derivatives on
ALDH3A1. We initiated a search for structural analogues of
CB7 in order to develop structure−activity relationships
(SARs) for this class of compound. We identiﬁed 118 diﬀerent
compounds that exhibited at least 90% structural similarity to
CB7. These compounds were tested for their potency toward
ALDH3A1 and selectivity versus ALDH1 and ALDH2
isoenzymes. Our initial kinetics study showed that the central
sulfonyl group substituted with a benzimidazole and benzene
ring were essential elements of CB7. Hence, we deﬁned these
three moieties as a core structure and looked for analogues with
substitutions from this core (Table 1). Our SAR showed that a
methyl group at the R1 position is optimal (compare A20 with
A21, and A10 with A3, Table 1), and larger substitutions were
not tolerated (compare A6 and A13 with A20, A21, B36, and
B37, Table 1). No substitutions were tolerated at the R2 and
R3 positions (A38 and A47). We suggest that other than small
halogens, which were not available for testing, substitutions at
the R2 and R3 positions are incompatible with inhibition of
ALDH3A1. We looked at analogues with diﬀerent chemical
substituents at the R6 position. Analogues with hydrogen,
methyl, isobutyl, and acetamide substitutions at this position do
not inhibit ALDH3A1; only compounds with ﬂuorine or
chlorine at the R6 position were inhibitors (compare A5, A3,
A16, and A67 with A21 and A24, Table 1). Substitutions at the
ortho (R4 or R8 position) were also detrimental to potency
(A30 versus A20, or A39 versus A24 or A40 with CB7).
Although substitution at the meta position (either R5 or R7)
was tolerated, they decreased inhibitory potency (A53 and A64
versus A20 or A70 versus CB7). In summary, no available
analogues exceeded the potency of the original hit molecule,
CB7. Importantly, none of the analogues inhibited ALDH1A2,
ALDH1A3, or ALDH1B1 at concentrations up to 100 μM. As a
consequence, with inhibition constants of ∼100 nM and with
no inhibitory eﬀect on the ALDH1 (ALDH1A1, ALDH1A2,
Figure 2. (A) Chemical structure of CB7. (B) IC50 plot for CB7 with respect to ALDH3A1 catalyzed benzaldehyde oxidation.
Figure 3. Mode of inhibition of CB7 toward ALDH3A1. (A) Lineweaver−Burk representation of the nonlinear ﬁt to the competitive inhibition
equation for CB7 (0−125 nM) versus varied benzaldehyde (100−1000 μM) at ﬁxed coenzyme concentration NADP+ (1.5 mM). (B) Lineweaver−
Burk representation of the nonlinear ﬁt to the noncompetitive inhibition equation for CB7 (0−200 nM) toward varied NADP+ (100−500 μM) at
ﬁxed benzaldehyde (1 mM). All experiments were performed in triplicate, and one representative experiment out of three is depicted.
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ALDH1A3, ALDH1B1) or ALDH2 isoenzymes, CB7 is an
excellent lead compound for the development of focused library
synthesis.
ALDH3A1 Crystal Structure with CB7 and NAD+.
1. CB7 Interaction with ALDH3A1. To complement our
kinetics experiments and further our understanding of the SAR
results, we solved the crystal structure of CB7 bound to
ALDH3A1. Since the inhibition pattern was competitive with
respect to varied benzaldehyde and noncompetitive with
respect to varied coenzyme, we cocrystallized ALDH3A1 in
the presence of both NAD+ and CB7. The complex formed as
monoclinic crystals and diﬀracted to 1.9 Å resolution. The
structure was determined by molecular replacement using the
apo ALDH3A1 structure as the search model (PDB code
3SZA). The asymmetric unit contains two independent dimers.
Each subunit contains a well-ordered NAD+ bound to the
coenzyme binding site of ALDH3A1 (Figure 4A and Figure
5A). In contrast, CB7, while present in each active site, is
modeled as half-occupied in each of the four subunits such that
its reﬁned B-factors match those of the surrounding amino acid
side chains that contact CB7 (Figure 4B and 4C). Detailed
reﬁnement statistics are provided in Table 2. In the
Ramachandran plot, 97.3% of all residues are in the most
favored regions. Perhaps underlying the less well-deﬁned
electron density is the fact that no hydrogen bonding
interactions were observed between CB7 and ALDH3A1;
rather, it would appear that extensive van der Waals and
hydrophobic interactions drive the association (Figure 4D),
which may lead to multiple binding modes, for which there is
weak diﬀerence density evidence surrounding the modeled
position of CB7 in each subunit. However, modeling of these
alternative binding modes does not improve the reﬁned model
structure and has not been included in the ﬁnal set of deposited
coordinates. The common binding mode for CB7 in the four
active sites shows that the benzimidazole moiety forms
hydrophobic contacts with Phe401, Tyr115, Leu119, Cys243,
His413, and Ile394. The methyl group associated with
imidazole ring forms hydrophobic interaction with Tyr65 and
Ile394. One of the sulfonyl oxygen atoms forms van der Waals
interactions with Tyr65, Glu62, and Asn118, while the other
sulfonyl oxygen forms van der Waals interactions with Tyr115,
Glu62, and Asn118. The ﬂuorobenzene group forms hydro-
phobic interactions with Tyr65 and Tyr115, as well as with
Thr395 and Glu61. The ﬂuorine atom forms van der Waals
contacts with Ile391, Trp233, and Met237 (Figure 4D). These
structural data were essential for understanding our SAR data.
Our SAR study showed that analogues with hydrogen, methyl,
isobutyl, acetamide substitution at R6 position do not inhibit
ALDH3A1 whereas ﬂuorine or chlorine substitution was able to
inhibit ALDH3A1 (compare A5, A3, A16, and A67 with A21
and A24, Table 1). Since chlorine and ﬂuorine are both small
and electron withdrawing atoms, we believe that these
substituents not only enhance the hydrophobic interactions
with Tyr65 and Tyr115 but also do not add suﬃcient bulk to
comprise the van der Waals interactions with Trp233 (A20
versus A22, Table 1).
2. NAD+ and Its Interaction with ALDH3A1. ALDH3A1 is
relatively unique among the human ALDH family members in
that it is capable of utilizing either NAD+ or NADP+ as
coenzyme. Only one other structure of ALDH3A1 has
coenzyme bound,34 but the nicotinamide ring is observed in
a nonproductive syn conformation. The structure of human
ALDH3A1 with bound NAD+ reported here is similar to other
ALDH family members in that the nicotinamide ring is held
near the catalytic cysteine (Cys243 in ALDH3A1) in the anti
conformation and is positioned in the hydride-transfer
conformation.35 In stark contrast to the interactions between
CB7 and ALDH3A1, many hydrogen bonding interactions are
observed between NAD+ and ALDH3A1. The amino nitrogen
from the nicotinamide moiety forms a hydrogen bond with
peptide carbonyl oxygen from Leu210, while the nicotinamide
carbonyl oxygen hydrogen-bonds with a water molecule that is
hydrogen-bonded to Thr186 and Tyr412. The two hydroxyl
groups from the nicotinamide ribose form two hydrogen bonds
with the side chain carboxylate oxygens of Glu333, as well as to
a water molecule. The pyrophosphate group forms ﬁve
hydrogen bonds with Thr112, Ser188, Trp113, and His289,
as well as an additional four hydrogen bonds with ordered
water molecules. The 2′ and 3′ hydroxyls from the adenosine
ribose moiety form two hydrogen bonds with the side chain of
Glu140, as well as four hydrogen bonds to ordered water
molecules. These latter interactions are likely modiﬁed when
the 2′-hydroxyl is phosphorylated, as would be in NADP+.
Hydrophobic interactions are contributed by Val169, Val191,
Ile194, and Thr172 to position the adenine ring, and the
Table 1. Structure−Activity Relationships for Analogues of
CB7a
aValues in parentheses represent standard error. NI stands for no
inhibition, and NI(A) stands for no inhibition but very weak activation
(∼20% at 100 μM). Residues of ALDH3A1 that are in close contact
with CB7 are shown in yellow boxes. None of the compounds tested
had any inhibitory eﬀect on ALDH1A2, ALDH1A3, or ALDH1B1.
Figure was generated using ChemBioDraw Ultra 12.0.
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nicotinamide ring is stabilized by hydrophobic and van der
Waals interactions with Thr186, Asn114, Cys243, Phe401,
Leu361, Thr112, Leu119, and Glu209 (Figure 5B).
Characterization of Q122A and Q122W Mutants. We
compared the crystal structure of human ALDH3A1 against
human ALDH2 (PDB code 1CW3) and sheep ALDH1A1
(PDB code 1BXS) to compare their active sites (Figure 9).
Upon structural alignment, we identiﬁed a critical tryptophan
(W177) that is present in both sheep ALDH1A1 and ALDH2
active site but not in ALDH3A1, which could explain the
selectivity of CB7 for ALDH3A1. In the ALDH3A1 active site,
a glutamine (Q122) residue is present in the corresponding
position (Figure 9). A sequence alignment of human and sheep
ALDH1A1 conﬁrmed that this tryptophan residue is conserved
in the human enzyme and is highly conserved across all human
ALDH isoenzymes (Figures S1 and S2). In order to investigate
the impact of glutamine/tryptophan at this position toward
CB7 binding in ALDH3A1, we mutated the glutamine to either
alanine or tryptophan. Kinetic parameters were determined for
benzaldehyde oxidation for the wild-type and mutant
ALDH3A1 enzymes (Table 3). We also determined the
inhibition constants for CB7 on these mutants (Table 3).
The alanine mutation did not show a drastic eﬀect on the
enzyme’s catalytic eﬃciency toward benzaldehyde or its ability
to bind CB7 (Table 3). However, when Gln122 was mutated to
tryptophan (Q122W), CB7 was not inhibitory up to 250 μM
for this mutant. In contrast, the mutant enzyme’s catalytic
eﬃciency toward benzaldehyde was only decreased 3-fold
compared to the wild-type enzyme. These data support the
hypothesis that the structure of the substrate-binding site
surrounding Q122 is responsible for imparting selectivity
toward CB7.
CB7 and Its Analogues Show Inhibition of Dehydro-
genase Activity in Cell Lysates. Lysates from series of cell
lines were analyzed for the levels of ALDH3A1 and ALDH1A1
protein expression, since these two enzymes are known to
contribute to cyclophosphamide metabolism. Three cell lines
were chosen as representatives of transformed and non-
transformed cells with diﬀerential ALDH isozymes expression:
A549, SF767, and CCD-13Lu. Our Western blot analysis
conﬁrmed that the A549 cell line (lung adenocarcinoma)
expresses both ALDH1A1 and ALDH3A1.36 The SF767 cell
Figure 4. Binding of CB7 to the active site of ALDH3A1 (PDB code 4L2O). (A) Surface representation of catalytic and NAD(P)+ binding site of
ALDH3A1. NAD+ is bound into the Rossmann fold, whereas CB7 binds into the catalytic pocket. Bound ligands are represented as sticks. (B)
Original σA-weighted electron density map prior to inclusion of CB7 in the model for reﬁnement contoured at 2.5 standard deviations (Fo − Fc,
green) at 1 standard deviation (2Fo − Fc, blue) superimposed onto the ﬁnal reﬁned model of CB7 bound in the enzyme active site. Residues that
contribute to hydrophobic interactions within a distance of 3.4−4.0 Å are represented as sticks. (C) Simulated annealing omit electron density map
calculated by the program PHENIX53 displaying the residual electron density (Fo − Fc, green, contoured at 2.5 standard deviations of the map and
2Fo − Fc, blue contoured at 1 standard deviation of the map) present in the active site of the ALDH3A1 structure superimposed onto the ﬁnal
reﬁned model of CB7 bound in the enzyme active site. (D) Two dimensional schematic representing hydrophobic (black arcs) and van der Waals
contacts (blue arcs) seen between CB7 and residues within the active site of ALDH3A1.
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line (glioblastoma) expresses only ALDH3A1,36 and the
primary human lung ﬁbroblasts (CCD-13Lu) showed no
detectable expression of either ALDH3A1 or ALDH1A1.36 In
fact, the antibody chosen for the ALDH1A1 Western blot
cross-reacts with ALDH1A2, ALDH1A3, ALDH1B1, and
ALDH2,36 so the SF767 cell line appears to be devoid of
most class 1 and class 2 ALDH expression. To examine the
ability of CB7 and selected analogues to function in a complex
milieu, we tested their ability to inhibit ALDH activity in cell
lysates using benzaldehyde and NADP+ as ALDH3A1 selective
substrates. Benzaldehyde is a substrate for both ALDH1A1 and
ALDH3A1, but ALDH1A1 does not use NADP+ as a
coenzyme; thus, this assay measures primarily ALDH3A1
activity. Consistent with our immunoblot experiments, A549
cells showed robust ALDH3A1 activity (282 nmol min−1
mg−1), which was equivalent to approximately 1% of the
cellular protein. SF767 cells also showed robust ALDH3A1
expression (1% of the total protein), whereas CCD-13Lu had
no ALDH3A1 activity (<2 nmol min−1 mg−1) consistent with
our immunoblot studies.36 The presence of CB7 and selected
analogues at 10 μM decreased the measurable activity in A549
cell lysates by >97% and in SF767 cell lysates by >93% (Figure
6). For comparison, the activity of puriﬁed recombinant
ALDH3A1 was decreased by more than 98% by the same 10
μM concentration of CB7 and CB7 analogues (Figure 6).
These data suggest that CB7 and its analogues can target
ALDH3A1 activity in the context of cellular lysates with
potencies similar to those observed in puriﬁed enzyme
preparations.
Sensitization of Tumor Cells to Mafosfamide through
Inhibition of ALDH3A1. Prior work had demonstrated that
the level of ALDH activity in tumor cells is correlated with the
level of resistance toward cyclophosphamide or its deriva-
tives.23,24,26,28 However, the extent to which ALDH3A1
contributes to this resistance has been the subject of some
debate15,21,24,37−39 even though RNA knockdown of both
ALDH1A1 and ALDH3A1 was required for maximal
sensitization of A549 cells toward aldophosphamide.15 Since
our new ALDH3A1 inhibitors demonstrated both good
potency and selectivity, we initiated studies designed to test
whether inhibition of ALDH3A1 alone could sensitize cells
toward cyclophosphamide derivative. For these studies, we used
mafosfamide, since this compound spontaneously generates
aldophosphamide in solution without the need for P450
activation. Treatment of A549, CCD-13Lu, and SF767 cells
with mafosfamide decreased cell proliferation of all three cell
lines (parts A, B, and C of Figure 7, DMSO control vs
mafosfamide, 48 ± 3% (A549), P < 0.0001; 46 ± 2% (SF767),
p < 0.0001; 56 ± 3% (CCD-13Lu), p < 0.0001). Except for
analogue A10, treatment of A549 cells with CB7 analogues
alone at 10 μM had no signiﬁcant eﬀect on cell proliferation.
However, when A549 cells were treated with mafosfamide in
the presence of 10 μM ALDH3A1 inhibitor, we observed
additional decreases in cell proliferation. A549 cells demon-
strated a dramatic decrease in cellular proliferation when
mafosfamide was used in combination with analogues CB7
(2.3-fold, p < 0.005), A64 (2.7-fold, p < 0.005), and A70 (2.4-
fold, p < 0.005) (Figure 7A). Similar experiments on SF767
Figure 5. Binding of NAD+ to ALDH3A1 (PDB code 4L2O). (A) Cofactor binding site of ALDH3A1 with NAD+ bound. The electron density maps
displayed are the original σA-weighted Fo − Fc map contoured at 2.5 standard deviations (green) and the original σA-weighted 2Fo − Fc map
contoured at 1 standard deviation (blue) superimposed on the ﬁnal reﬁned model of NAD+ bound in the enzyme active site. Selected residues
involved in strong hydrogen bonding interactions and hydrophobic interactions are shown. (B) Two-dimensional map showing all the hydrogen
bonds between NAD+ and ALDH3A1. Hydrogen bonds with a distance of <3.2 Å are shown by blue dotted lines.
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cells showed signiﬁcantly increased chemosensitivity with
analogues A10, A20, A21, CB7, A64, A70, and B37. Analogues
CB7, A64, and A70 were the most potent analogues in A549
cells and in SF767 cells, suggesting eﬀective inhibition of
ALDH3A1. Although we see some eﬀect on SF767 cells by
CB7 (1.25-fold, p < 0.05) and A64 (1.2-fold, p < 0.05) as single
agents (Figure 7B), in proliferation-based experiments, eﬀects
of these compounds along with mafosfamide were much more
dramatic (Figure 7B, MF 46 ± 2% vs MF + ALDH3A1
inhibitor 2 ± 1% (CB7), P < 0.005; 6 ± 1% (A64), P < 0.005; 3
± 1% (A70), P < 0.005)). This eﬀect was also cell line speciﬁc,
since we did not see this pattern in A549 and CCD-13Lu cells.
In the case of CCD-13Lu cells, increased chemosensitization
was not observed with CB7 analogues. However, analogue A10
decreased cell proliferation (1.1-fold, p < 0.05) when these cells
were treated with 10 μM ALDH3A1 inhibitor along with
mafosfamide (Figure 7C). SF767 cells were more sensitive to
mafosfamide as measured by MTT assay when treated with
ALDH3A1 inhibitors than were A549 cells (compare Figure 7A
and 7B), which is consistent with more than one active ALDH
Table 2. X-ray Data Collection and Reﬁnement Statistics for
ALDH3A1 Bound to CB7
data collection ALDH3A1 (CB7 cocrystal)
space group P21
cell dimensions
a (Å) 95.2
b (Å) 90.9
c (Å) 117.9
β (deg) 112.4
resolution (Å) 108.96−1.95
Rmerge 0.072 (0.35)
I/σI 10.9 (4.5)
completeness (%) 96.3
redundancy 2.8
Reﬁnement
resolution (Å) 108.96−1.95
no. of reﬂections 125475
Rwork/Rfree 0.21/0.25
no. of atoms
protein 14073
ligand/ion 267
water 979
average B-factors
protein 30.4
coenzyme 33.9
ligand (CB7) 34.2
water 33.6
rmsd bond (deg) 1.07
rmsd bond length (Å) 0.005
Table 3. Kinetics Data for ALDH3A1 and the Q122A and
Q122W Mutant Enzymes
KM
benzaldehyde (μM) kcat/KM (min
−1 μM−1) Ki
CB7 (μM)
WT 279 ± 23 4.91 ± 0.25 0.2
Q122A 425 ± 38 3.2 ± 0.13 0.2
Q122W 257 ± 35 1.73 ± 0.27 NI
Figure 6. Activity of ALDH3A1 in cell lysates. A549, SF767, and
CCD-13Lu cell lysate activity as well as recombinant ALDH3A1
activity was tested in the presence of 1.5 mM NADP+ and 1 mM
benzaldehyde and in the presence and absence of 10 μM CB7 and its
analogues. CCD-13Lu did not show any NADP+ catalyzed
benzaldehyde oxidation. The p-values were calculated using the
Student’s t test comparing activity in the absence and presence of
ALDH3A1 inhibitor (∗, p < 0.0001, n = 3).
Figure 7. Eﬀect of CB7 and analogues on cell proliferation. A549 (A),
SF767 (B), and CCD-13Lu (C) cells were treated with mafosfamide
concentration that corresponded to their ED50 values. Treatment was
done in the presence and absence of ALDH3A1 inhibitors (10 μM).
MTT assay was used to determine cell proliferation. Vehicle (DMSO)
concentration was limited to 0.25% (v/v). The p-values were
calculated by comparing the cellular proliferation of DMSO treated
cells versus inhibitor treated cells (∗, p < 0.05, n = 15) or mafosfamide
(MF) treated cells versus MF + 10 μM ALDH3A1 inhibitor treated
cells (∗∗, p < 0.005, n = 15). Black bars represent compound
treatment alone, and gray bars represent compound and mafosfamide
treatment, mean value ± SE.
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isozyme present in A549 cells. To conﬁrm targeted binding, we
determined the dose dependency for three compounds in A549
and SF767 cells (Figure 8A). We observed a dose-dependent
decrease in cell proliferation in both A549 and SF767 cell lines,
albeit more pronounced in SF767 cells which express
predominantly ALDH3A1. To calculate the shift in ED50
value of mafosfamide in the presence of ALDH3A1 inhibitors,
we treated SF767 cells with increasing amounts of mafosfamide
in the presence or absence of CB7, A64, and A70 at 10 μM.
Results showed that in the presence of ALDH3A1 inhibitors,
ED50 values of mafosfamide drop signiﬁcantly: 1.5-fold for CB7,
1.9-fold for A64, and 2-fold for A70 (ED50 values: 146 ± 2 μM
(MF) vs 96 ± 6 μM (MF + CB7), 75 ± 5 μM (MF + A64), 74
± 4 μM (MF + A70)) (Figure 8B). The consequence of this
increased sensitivity is that SF767 cell proliferation decreases
from 50% with mafosfamide alone (150 μM) to less than 10%
when ALDH3A1 is selectively inhibited in combination with
mafosfamide treatment.
■ DISCUSSION AND CONCLUSION
Cyclophosphamide is one of the most successful and widely
utilized antineoplastic agents. In addition to its antineoplastic
property, it is also a potent immunosuppressant and is used
during bone marrow transplantation. Varied cellular expression
of aldehyde dehydrogenase has an adverse eﬀect in anticancer
therapeutics and immunosuppressive properties of cyclo-
phosphamide. Cyclophosphamide is activated by cytochrome
P450 enzymes to the intermediate 4-hydroxycyclophosphamide
(Figure 1). 4-Hydroxycyclophosphamide undergoes sponta-
neous isomerization to form aldophosphamide. Aldophospha-
mide can undergo β-elimination to form acrolein and
phosphoramide mustard (Figure 1), the latter of which forms
double-stranded DNA cross-links and stalls replication.
Alternatively, aldophosphamide can be metabolized by
aldehyde dehydrogenase isozymes to the less toxic carbox-
yphosphamide metabolite (Figure 1). As a consequence of their
ability to metabolically inactivate aldophosphamide, ALDH
isozymes (especially ALDH1A1 and ALDH3A1) are known for
their ability to induce resistance toward derivatives of
cyclophosphamide.15,17,24,26,28 To overcome this resistance,
increased levels of cyclophosphamide are required, but these
higher concentrations lead to severe side eﬀects such as anemia,
leukopenia, and neutropenia due to bone marrow toxicity.17
Other eﬀects include cardiac toxicity,40 gonadal failure,41
bladder toxicity,42 and complications such as peripheral
neuropathy.43 Therefore, selective inhibition of the active
metabolic pathways present in speciﬁc tumors that lead to the
inactivation of cyclophosphamide may permit lower eﬀective
dosages and potentially reduce the unwanted side eﬀects.
Prior work showed that nonselective inhibition of aldehyde
dehydrogenase can sensitize A549 cells to the cytotoxic eﬀects
of mafosfamide.32 Other in vitro and cell-based work
demonstrated that both ALDH1A1 and ALDH3A1 contribute
to aldophosphamide metabolism, although the contributions of
ALDH1A1 is thought to be higher than that of ALDH3A1.39
This is also consistent with RNAi knockdown studies where
reductions in both ALDH1A1 and ALDH3A1 were required for
maximal sensitivity to aldophosphamide.15 Identiﬁcation of cell
permeable selective inhibitors for ALDH3A1 and ALDH1A1
isozymes may therefore help us understand their individual
contributions toward aldophosphamide metabolism and could
lead to targeted therapies for increasing chemoresistance in
selected tumors with speciﬁc ALDH isozyme expression.
Figure 8. Dose response of CB7, A64, and A70 for mafosfamide
sensitization. (A) A549 and SF767 were treated with MF (ED50
concentration) with increasing concentration of analogues CB7, A64,
and A70. The p-values were calculated by comparing the cellular
proliferation of DMSO treated cells versus inhibitor treated cells (∗, p
< 0.05, n = 15) or MF treated cells versus MF + ALDH3A1 inhibitor
treated cells (∗∗, p < 0.005, n = 15). Black bars represent ALDH3A1
inhibitor treatment alone, and gray bars represent ALDH3A1 inhibitor
plus MF treatment, mean value ± SE. (B) SF767 cells were treated
with CB7, A64, and A70 at 10 μM with increasing concentration of
MF. Cell proliferation was determined using MTT assay, and plot for
percent (%) proliferation was created using the SigmaPlot (version 11,
StatSys). Shaded circles (●) show SF767 cell proliferation treated with
mafosfamide in the absence of inhibitors. Open circles (○), inverted
shaded triangles (▼), and open triangles (△) show cell proliferation
with MF in the presence of inhibitors CB7, A64, and A70,
respectively. The solid trend lines (MF + DMSO (black), MF +
CB7 (pink), MF + A64 (green), MF + A70 (blue)) represent the ﬁts
to the three-parameter logistics equation. DMSO concentration was
limited to 0.25% (v/v) (n = 15). Figures were generated using
SigmaPlot, version 11.0.
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In our study, we have identiﬁed and characterized a selective
inhibitor of ALDH3A1 having submicromolar potency, CB7.
Kinetics analysis showed that our inhibitor is competitive with
respect to aldehyde substrates and noncompetitive with respect
to cofactor binding. This is further supported by the
crystallographic results that show binding within the aldehyde
substrate-binding site. Surprisingly, SAR studies on analogues
of CB7 showed that our original hit compound, CB7, was the
most potent analogue available. We used the structural
information available from CB7·ALDH3A1·NAD+ crystal
structure to further illuminate the SAR on this class of
compound. The proximity of the benzyl substituent of the
benzimidazole moiety to Cys243, Phe401, Leu119, and Tyr115
explains the detrimental eﬀects of adding substituents to the R2
and R3 positions (Table 1 and Figure 4). Moreover, the
nicotinamide carbonyl oxygen is 3.9 Å from the benzimidazole
ring such that a methyl group at the R2 position would create
steric overlap with this portion of the NAD+ molecule. In
addition, the side chain of Tyr65 limits substitutions at the R1
and R4/R8 positions (Table 1, Figure 4C, and 4D). Similarly,
the side chain of Tyr115 impacts the available space
surrounding the ortho R4/R8 positions. On the other hand,
substitutions at the R5 and R6 positions are tolerated because
of the small cavity between Trp233 and Tyr65. Our SAR study
suggests that smaller substitutions, preferably electron with-
drawing halogens, were optimal at the R6 position because of
the presence of Trp233 and Met237 at distances of 4 and 3.5 Å
from the R6 position, respectively. Overall, our SAR supports
the structural data presented here and interpretation of the SAR
based on this structure is fully consistent with CB7 being the
most potent compound of the series. We also identiﬁed Gln122
as a major contributor to the internal topology of ALDH3A1
that accounts for selectivity of CB7 for ALDH3A1 versus
ALDH1A1 or ALDH2. In particular, a sequence alignment of
all human ALDH protein sequences (Figure S2) demonstrates
that a Trp residue at the position equivalent to W177 in
ALDH2 and ALDH1A1 is present in 12 of the 19 human open-
reading frames. Only ALDH3A1, ALDH3A2, and ALDH18A1
have Gln at this position, while ALDH3B1, ALDH3B2, and
ALDH4A1 have smaller hydrophobic residues and ALDH5A1
has an Arg at this position. Consequently, selectivity of CB7
toward all human ALDH isoenzymes is likely to be high and
may only adversely impact ALDH3A2 and ALDH18A1, the
latter of which is not yet known to be active and lacks key active
site residues in sequence alignments.
Several ALDH3A1 inhibitors reported here enhance the
antiproliferative eﬀects of mafosfamide but had little if any
eﬀects on cellular proliferation at the doses tested in our assays.
Presumably, this eﬀect is mediated by their ability to inhibit the
metabolism of mafosfamide by ALDH3A1. In particular, SF767
cells used in this work express only ALDH3A1 and
demonstrated the greatest level of chemosensitization. How-
ever, even A549 cells, which express both ALDH1A1 and
ALDH3A1, could be sensitized by these same compounds.
ALDH3A1 is not the only means by which mafosfamide can be
inactivated, and this is demonstrated by the partial sensitization
observed in A549 cells, relative to the same treatments in
SF767 cells. In contrast, these same compounds show neither
general toxicity nor enhancement of chemosensitivity in
primary human lung ﬁbroblasts (CCD-13Lu), which do not
express either ALDH1A1 or ALDH3A1. High levels of ALDH
expression in both SF767 and A549 cells (about 1% of total
soluble protein) compared to the undetectable expression in
normal human lung ﬁbroblasts also point to the involvement of
these ALDH isoforms as markers of transformed cells. Whether
the general expression of ALDH isozymes is required for the
maintenance of the transformed phenotype or simply a
consequence of a change in global gene expression is less
clear. However, the involvement of ALDH isoforms in
mafosfamide resistance is supported by several lines of
evidence.23,24,26,28 Certainly, the correlation between ALDH
expression and sensitivity toward mafosfamide can be seen in
the fact that human lung ﬁbroblasts (CCD-13Lu) have the
lowest ED50 value for mafosfamide at 40 μM, whereas A549
and SF767 tumor cell lines were considerably more resistant
with ED50 values of 125 and 146 μM, respectively, for
mafosfamide. ALDH3A1 can be a major contributor to
mafosfamide metabolism as observed in SF767 glioblastoma
cell line. The presence of CB7, A64, or A70 at 10 μM lowers
the ED50 for mafosfamide to 96 ± 6, 75 ± 5, or 74 ± 4 μM,
respectively (Figure 8B). In fact, the simultaneous presence of
an ALDH3A1 inhibitor and 150 μM mafosfamide reduces cell
proliferation to less than 5% of control. Consequently, selective
inhibition of ALDH3A1 can provide a means to enhance the
antiproliferative eﬀects of mafosfamide in selected tumor types
and perhaps permit therapies to proceed with reduced marrow
toxicity.
■ EXPERIMENTAL SECTION
Materials. Reagents such as benzaldehyde, propionaldehyde, p-
nitrophenyl acetate, NAD+, NADP+, and buﬀers were all purchased
from Sigma Aldrich unless otherwise stated. PEG3350 for crystal-
lization trial was purchased from Hampton Research.
Cell Lines. A549, CCD-13Lu, and SF767 cell lines were provided
by Dr. Hua Lu, ATCC, and Dr. Karen Pollok, respectively. A549 and
CCD-13Lu cells were cultured in DMEM (Cellgro, Mediatech Inc.,
Manassa, VA) supplemented with 10% fetal bovine serum (FBS)
(Gibco, Invitrogen Company, Grand Island, NY), 100 units/mL
penicillin, and 10 μg/mL streptomycin. SF767 cell lines were cultured
in IMDM (Gibco, Invitrogen Company, Grand Island, NY)
supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen
Company, Grand Island, NY), 100 units/mL penicillin, and 10 μg/mL
streptomycin. Cell viability as assessed by tryphan blue exclusion was
consistently >95%. Cells were passaged after reaching 80−90%
Figure 9. Structural superimposition of the active sites of human
ALDH2 (PDB code 1CW3) and sheep ALDH1A1 (PDB code 1BXS)
and human ALDH3A1 (PDB code 3SZA). The molecular surface for
ALDH3A1 is displayed using atom-type coloring (carbon, magenta;
nitrogen, blue; oxygen, red; sulfur, yellow). The structures of sheep
ALDH1A1 (carbon, cyan) and human ALDH2 (carbon, yellow) were
represented using alternative atom-type coloring.
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conﬂuence, which usually took 3−4 days for A549 and SF767 cell lines
and 8−12 days for CCD-13Lu cells.
Protein Expression and Activity Measurement. Human
ALDH1A1, ALDH2, and ALDH3A1 were expressed and puriﬁed as
described elsewhere.32,33,44 Human ALDH1A2, ALDH1A3, and
ALDH1B1 were expressed and puriﬁed as described elsewhere.36
The enzymatic activities of ALDH1A1, ALDH2, and ALDH3A1 were
monitored by calculating the increase in absorbance at 340 nm due to
NAD(P)H formation (molar extinction coeﬃcient of 6220 M−1 cm−1)
as described earlier.33,44 The activities of ALDH1A2, ALDH1A3, and
ALDH1B1 were monitored as described elsewhere.36 The speciﬁc
activities of the puriﬁed proteins were 1.9, 0.80, 0.44, 0.20, 3.8, and 32
μmol min−1 mg−1 for ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1,
ALDH2, and ALDH3A1 respectively.
Inhibitors. CB7, the most potent and selective ALDH3A1
inhibitor discovered in our initial chemical screen,33 was purchased
from ChemBridge Corp. This compound had three important
moieties: 2-methylbenzimidazole, sulfonyl, and ﬂuorophenyl groups.
In our initial search, we looked for analogues that had two of these
three moieties to see which moiety would contribute the most in terms
of selectivity and potency. The second round of search was conducted
for analogues that had all these three moieties connected the exact
same way but that had small substitutions at various positions. All
these analogues had at least 95% structural similarity to CB7. Over 118
compounds were purchased from ChemBridge Corp. and ENAMINE
Ltd., Kiev, Ukraine, Princeton Biomolecular Research Ltd., Life
Chemicals, and Vitas M. Laboratories. The purity of the compounds
according to the vendor was >95%. Compounds were dissolved and
diluted in 100% DMSO and stored at −20 °C. The analogues were
tested for their selectivity against ALDH1A1, ALDH1A2, ALDH1A3,
ALDH1B1, ALDH2, and ALDH3A1 at 100 μM. Compounds
discussed in this study with their respective vendor and corresponding
catalog numbers are listed in Table S1 in Supporting Information.
Determination of Kinetics Parameters. IC50 values were
determined for CB7 and its analogues using propionaldehyde as a
substrate for ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, and
ALDH2 and using benzaldehyde as a substrate for ALDH3A1. For
these IC50 determinations, the enzymatic activities of ALDH1A1,
ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, and ALDH3A1 were
monitored by calculating the increase in absorbance at 340 nm due to
NAD(P)H formation (molar extinction coeﬃcient of 6220 M−1 cm−1)
on a Beckman DU-640 spectrophotometer in the presence of various
concentrations of inhibitors ranging from 50 nM to 100 μM following
a 1 min preincubation. ALDH1A2, ALDH1A3, and ALDH1B1 activity
assays were measured spectrophotometrically in reaction solution
containing 1 mM propionaldehyde, 1.5 mM NAD+, and 200 nM
ALDH1A2, 150 nM ALDH1A3, and 200 nM ALDH1B1 of respective
enzymes all in the presence of 25 mM BES buﬀer, pH 7.5. ALDH1A1
and ALDH2 activities were measured spectrophotometrically in a
solution containing 200 nM enzyme, 1 mM propionaldehyde, 1.5 mM
NAD+ all in the presence of 50 mM sodium BES at pH 7.5.33,44,45
ALDH3A1 activity was measured in 10 nM ALDH3A1, 1 mM
benzaldehyde, and 1.5 mM NADP+ in 100 mM sodium phosphate
buﬀer, pH 7.5.33,44,45 Reaction was initiated by the addition of the
aldehyde substrate. There was no preincubation time-dependence to
the inhibition. The inhibition curves were ﬁt to the logistic four-
parameter IC50 equation using the SigmaPlot (version 11, StatSys).
Steady state kinetics experiments were performed by covarying
inhibitor and substrate concentrations. The steady state kinetics
measurements were performed in 100 mM Na2HPO4 buﬀer, pH 7.5.
The reaction mixture contained 6 nM ALDH3A1, varied benzaldehyde
(100−800 μM under ﬁxed NADP+, 1.5 mM) at varied inhibitor
concentration (0−200 nM), or varied NADP+ (100−500 μM; ﬁxed
benzaldehyde, 1 mM) at varied inhibitor concentrations (0−200 nM).
All experiments including the controls contained 2% (v/v) DMSO.
The initial rate of product formation was determined on a Beckman
DU-640. All data were ﬁt to the nonlinear velocity expressions for
competitive, noncompetitive, mixed-type noncompetitive and un-
competitive inhibition.46 Appropriateness of the inhibition model was
determined through analysis of goodness-of-ﬁt and the residuals of
those ﬁts. Lineweaver−Burke plots were created using SigmaPlot
(version 11, StatSys) to visualize the inhibition patterns. All data
represent the average of three independent experiments utilizing
triplicate assays at each concentration point.
Crystallization of ALDH3A1 with NAD+ and CB7. ALDH3A1
crystals were grown from solutions containing 0.2 M potassium
acetate, 20% PEG 3350 at 25 °C. The enzyme concentration was 4
mg/mL in 10 mM HEPES buﬀer, pH 7.5. The enzyme was mixed with
1 mM NAD+ and 1 mM CB7. Sitting drop experiment was performed
with 8 μL drop size and 1000 μL of mother liquor. Crystals were
obtained in about a week. These crystals were frozen directly in
gaseous nitrogen stream at 100 K without additional cryoprotectant.
Data sets were collected at a wavelength of 0.9869 Å at 100 K at the
Advanced Photon Source using beamline 19-ID operated by the
Structural Biology Consortium Collaborative Access Team (SBC-
CAT) located at Argonne National Laboratory. The diﬀraction data
were indexed, integrated, and scaled using the HKL3000 program.47
Because of the presence of weak ice−ring diﬀraction in the images, the
following macros were introduced into HKL3000, “reject fraction
0.70” and “reject slope 100”, in order to integrate through the slightly
higher background in these regions of the diﬀraction images. All
reﬁnements were performed using the program package REFMAC548
as implemented in the CCP4 program suite,49 and model inspection
and building were accomplished using Coot.50 The structure was
solved by performing molecular replacement using the apo form of
ALDH3A1 structure as the search model (PDB code 3SZA).
Molecular replacement was performed using MOLREP program51
provided by CCP4 software.49 Initial maps showed clear electron
density for the CB7 bound in the active site of two out of four
monomers present in the asymmetric unit. The other two active sites
showed weaker electron density consistent with partial occupancy, and
CB7 was modeled into these active sites during later stages of
reﬁnement. All ligands demonstrated diﬀerence density features
consistent with multiple conformers bound within each active site.
However, the resolution of the data is insuﬃcient for modeling of
multiple conformations at occupancies of less than 50%. Con-
sequently, the highest occupancy conformer is modeled into each
active site and is assigned an occupancy value of 0.5, based on a
comparison between the reﬁned B-factors for the ligands and those of
the surrounding active site residue side chains that are in contact with
CB7. Water molecules were added after the addition of ligands in
order to prevent inadvertent placement of water molecules into
density features that represent the ligand. Ligands were sketched in
Sketcher, as implemented in CCP4.49 This structure was used to create
the library description ﬁle used in reﬁnement.
Generation of Q122A and Q122W Mutants. In order to
characterize the binding pattern of CB7 to catalytic site of ALDH3A1,
two important mutations Q122A and Q122W were made. Point
mutations of ALDH3A1 were performed using QuickChange
(Qiagen) mutagenesis. ALDH3A1 mutants were constructed using
forward primer 5′-CTT CAA CCT CAC CAT CGC GCC CAT GGT
GGG CGCC-3′ and complement for Q122A and forward primer 5′-
CCT TCA ACC TCA CCA TCT GGC CCA TGG TGG GCG CCA
TC-3′ and complement for Q122W mutant. These two mutant
proteins were puriﬁed exactly the same way as was ALDH3A1.
However, the yield was signiﬁcantly decreased compared to WT
protein. Q122A was stored at 0.9 mg/mL and Q122W was stored at
0.4 mg/mL at −80 °C. Kinetics experiments were performed exactly
the same way as the wild-type (WT) enzyme.
Analysis of ALDH3A1 Catalyzed Dehydrogenase Activities
from Cell Lysates. Brieﬂy, cells (A549, SF767, and CCD-13Lu) were
washed with ice cold PBS to remove residual medium. Then 400 μL of
RIPA buﬀer (Cell Signaling Technologies) containing 1 mM PMSF
(Sigma Aldrich) was added to each 10 cm dish. Plates were incubated
on ice for 5 min and scraped, and lysates were collected. Lysates were
centrifuged for 10 min at 16000g in a microcentrifuge at 4 °C. Protein
concentrations were measured using the Bradford reagent (Biorad
Laboratories). Then 50 μg of cell lysate was used in the activity assay.
ALDH3A1 activity in cell lysates was measured in 100 mM Na2HPO4
buﬀer at pH 7.5, with 1.5 mM NADP+ and 1 mM benzaldehyde.
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Activity assay was also performed with 1 μg of recombinant ALDH3A1
in the presence and absence of CB7 and its analogues A10, A20, A21,
B27, A64, A70, and B37. All assays including the controls contained
1% (v/v) DMSO. These compounds were tested at 10 μM to monitor
the extent of ALDH inhibition in these cell lysates and puriﬁed
ALDH3A1. Lysates were treated with these compounds for 1 min
before the substrate was added.
Mafosfamide Sensitivity Experiments. MTT assay was used for
conducting mafosfamide chemosensitivity experiments. Mafosfamide
was used for this study primarily because it is an analogue of
cyclophosphamide and it does not require cytochrome P450 for its
activation, which is ideal for cell based studies.52 Three cell lines, A549,
SF767, and CCD-13Lu, were chosen for this study. These cell lines
were chosen because A549 expresses both ALDH1A1 and
ALDH3A115 and SF767 expresses only ALDH3A1, whereas CCD-
13Lu expresses neither of these enzymes.36 CCD-13Lu cells were also
relevant for this study because they are normal lung ﬁbroblasts which
serve as a proper control for A549, which is a carcinogenic cell line
from lung. Our standardization measurements showed that 5000 cells/
well is optimal for A549 and CCD-13Lu and that 10 000 cells/well is
optimal for the SF767 cell line for a linear response of MTT assay.
Approximate ED50 values for adenocarcinoma (A549), glioblastoma
(SF767), and CCD-13Lu cells were 125, 150, and 40 μM,
respectively.36 After optimization experiments, A549 (5000 cells/
well), SF767 (10 000 cells/well), and CCD-13Lu (5000 cells/well)
were seeded in 96-well plates. Twenty-nine hours later, A549, SF767,
and CCD-13Lu cells were treated with 10 μM ALDH3A1 inhibitors
(A10, A20, A21, A64, A70, B27, B37, and CB7) in the absence or in
the presence of mafosfamide corresponding to their ED50 values.
These compounds were chosen for chemosensitivity experiments
because they showed the highest potency and selectivity in our SAR
experiments and were closely related to each other. MTT assay was
performed 19 h after ALDH3A1 inhibitor treatment to access cellular
proliferation.32 The relative percentage of cell proliferation was
calculated in comparison to DMSO (0.25%) treated controls.
DMSO concentration was strictly limited to 0.25% for these
experiments, which had no signiﬁcant eﬀect on cell viability by itself
(data not shown). The time points for treatment were chosen based
on similar experiments performed earlier.32
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